{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-081680","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.450462+00:00","generated_at":"2026-05-31T17:50:22.670088+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR","bullets":["CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.","ORR of 80% and disease control rate 98.2% in heavily pre-treated WM patients (median 4 prior therapies).","78% of major responders progression-free at 18 months; median DoR not reached.","Company plans to submit NDA in Q4 2024 and seek priority review.","Preliminary cash and equivalents ~$25.9M as of June 30, 2024 (unaudited, subject to change)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-081680","json":"https://secwatch.observer/filing/0001104659-24-081680.json","markdown":"https://secwatch.observer/filing/0001104659-24-081680.md","text":"https://secwatch.observer/filing/0001104659-24-081680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/0001104659-24-081680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/tm2419979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:50:22.670088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}